BR9805875A - Composições farmacêuticas de droloxifeno. - Google Patents
Composições farmacêuticas de droloxifeno.Info
- Publication number
- BR9805875A BR9805875A BR9805875-4A BR9805875A BR9805875A BR 9805875 A BR9805875 A BR 9805875A BR 9805875 A BR9805875 A BR 9805875A BR 9805875 A BR9805875 A BR 9805875A
- Authority
- BR
- Brazil
- Prior art keywords
- droloxifene
- pharmaceutical compositions
- preferred
- compositions
- dry
- Prior art date
Links
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical group C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 title abstract 4
- 229950004203 droloxifene Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- VNDHXHMRJVTMTK-WZVRVNPQSA-H hexasodium 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10-(hydroxymethyl)-15,20,25,30,35-pentakis(4-sulfonatobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]1[C@H](O)[C@H]2O VNDHXHMRJVTMTK-WZVRVNPQSA-H 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/06—Diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/42—Arrangements for detecting radiation specially adapted for radiation diagnosis
- A61B6/4208—Arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector
- A61B6/4233—Arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector using matrix detectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21K—TECHNIQUES FOR HANDLING PARTICLES OR IONISING RADIATION NOT OTHERWISE PROVIDED FOR; IRRADIATION DEVICES; GAMMA RAY OR X-RAY MICROSCOPES
- G21K1/00—Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
- G21K1/02—Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diaphragms, collimators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- High Energy & Nuclear Physics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Mathematical Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Patente de Invenção: <B>"COMPOSIçõES FARMACêUTICAS DE DROLOXIFENO"<D>. Composições de matéria que compreendem droloxifeno ou um seu sal farmaceuticamente aceitável e uma ciclodextrina. As ciclodextrinas preferidas são SBECD e HPBCD. A composição pode compreender uma mistura seca, um complexo de inclusão seco ou uma solução aquosa. O sal citrato de droloxifeno é preferido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6660097P | 1997-11-26 | 1997-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9805875A true BR9805875A (pt) | 2000-05-02 |
Family
ID=22070532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9805875-4A BR9805875A (pt) | 1997-11-26 | 1998-11-25 | Composições farmacêuticas de droloxifeno. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6077871A (pt) |
| EP (1) | EP0931545A3 (pt) |
| JP (1) | JPH11240833A (pt) |
| BR (1) | BR9805875A (pt) |
| CA (1) | CA2254434A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4922507B2 (ja) * | 2000-08-10 | 2012-04-25 | 武田薬品工業株式会社 | 医薬組成物 |
| WO2002013816A1 (fr) | 2000-08-10 | 2002-02-21 | Takeda Chemical Industries, Ltd. | Composition pharmaceutique |
| US7704975B2 (en) * | 2000-12-19 | 2010-04-27 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US7141555B2 (en) | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US6884885B2 (en) | 2000-12-21 | 2005-04-26 | Cerestar Holding B.V. | Production of cyclodextrin complexes |
| DE10215942A1 (de) * | 2002-04-11 | 2003-10-23 | Bayer Ag | Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat |
| CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| RU2006141358A (ru) | 2004-04-23 | 2008-05-27 | Сайдекс, Инк. (Us) | Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина |
| WO2006052921A2 (en) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Cyclodextrin solubilizers for liquid and semi-solid formulations |
| US20060105992A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US7658913B2 (en) | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
| EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
| EP2726106B1 (en) * | 2011-07-01 | 2015-07-29 | Fondazione Istituto Insubrico di Ricerca per la Vita | A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof |
| PE20151024A1 (es) * | 2012-11-30 | 2015-07-27 | Glaxosmithkline Llc | Composicion farmaceutica novedosa |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3046719C2 (de) * | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
| JPH04312526A (ja) * | 1991-04-09 | 1992-11-04 | Fujisawa Pharmaceut Co Ltd | 骨疾患治療剤 |
| GB9126209D0 (en) * | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| IT1263831B (it) * | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
| CZ306394A3 (en) * | 1993-12-14 | 1995-08-16 | Lilly Co Eli | Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof |
| US5384332A (en) * | 1994-05-11 | 1995-01-24 | Eli Lilly And Company | Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives |
| US5426123A (en) * | 1994-05-11 | 1995-06-20 | Eli Lilly And Company | Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives |
| US5455275A (en) * | 1994-05-11 | 1995-10-03 | Eli Lilly And Company | Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives |
| CA2223595C (en) * | 1995-06-07 | 2008-08-05 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
-
1998
- 1998-07-02 US US09/109,447 patent/US6077871A/en not_active Expired - Fee Related
- 1998-11-12 EP EP98309252A patent/EP0931545A3/en not_active Withdrawn
- 1998-11-24 CA CA002254434A patent/CA2254434A1/en not_active Abandoned
- 1998-11-24 JP JP10332135A patent/JPH11240833A/ja active Pending
- 1998-11-25 BR BR9805875-4A patent/BR9805875A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2254434A1 (en) | 1999-05-26 |
| EP0931545A2 (en) | 1999-07-28 |
| EP0931545A3 (en) | 2000-08-23 |
| US6077871A (en) | 2000-06-20 |
| JPH11240833A (ja) | 1999-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9805875A (pt) | Composições farmacêuticas de droloxifeno. | |
| EA199800910A1 (ru) | Композиции, комплексы включения фармацевтически приемлемой соли зипразидона и циклодекстрина и соли зипразидона | |
| RU94028890A (ru) | Композиции производных циклодекстрина, композиции, содержащие лекарство и производные циклодекстринов | |
| BR9809468A (pt) | Formulações farmacêuticas contendo voriconazol | |
| BR9909565A (pt) | Derivados bicìclicos do ácido hidroxâmico | |
| CA2289202A1 (en) | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent | |
| ATE87319T1 (de) | Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate. | |
| BRPI0215331B8 (pt) | composições aquosas contendo metronidazol | |
| BR9713338A (pt) | Benzonaftiridinas como terapêuticos brÈnquicos. | |
| ES2184293T3 (es) | Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina. | |
| BR9911040A (pt) | 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos | |
| BR0007294A (pt) | Formulações farmacêuticas aperfeiçoadas | |
| YU72594A (sh) | Vodeni rastvor inkluzionih kompleksa benzotiofen jedinjenja sa vodorastvornim ciklodekstrinima, njegove farmaceutske formulacije i postupci za dobijanje | |
| DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
| BR9811589A (pt) | Derivados de hidroxicumaranona o-substituìda como agentes antitumores e antimetastáticos | |
| BR0210293A (pt) | Uma preparação farmacêutica aquosa de cilostazol para utilização parenteral | |
| BR9914929A (pt) | Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas | |
| TR200000153T2 (tr) | İl-5 inhibite eden 6-azaurasil türevleri. | |
| BR0011845A (pt) | Complexo farmacêutico | |
| BR0012692A (pt) | Conjugado de protease, composição de limpeza e composição de tratamento pessoal | |
| BR0307172A (pt) | Composição farmacêutica contendo 2,2-dicloro-12-(4-clorofenil)-ácido dodecanóico | |
| ECSP972098A (es) | Complejos de inclusion de sales de aril meterociclicos | |
| HUP9903230A2 (en) | Diclofenac/gamma-cyclodextrin inclusion compounds and pharmaceutical compositions containing the same | |
| MY152490A (en) | New oral formulation | |
| BR0101116A (pt) | Composição de diluente/peróxido, sólida, de livreescoamento; e; uso de uma composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A, 4A, 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1872 DE 21/11/2006. |